Clinical Pearls and Key Takeaways on Kidney Cancer Treatment
Sumanta Kumar Pal, MD, FASCO, provides advice for community oncologists, and the Oncology Brothers review key points from the discussion.
Advanced Kidney Cancer: Treatment in the Second Line and Beyond
Focusing on advanced kidney cancer, medical oncologists offer clinical perspectives on treatment in the second line and beyond.
Treatment Algorithm for Metastatic Kidney Cancer
The Oncology Brothers and Sumanta Kumar Pal, MD, FASCO, offer comprehensive insights on the treatment of patients with metastatic kidney cancer.
Post-Surgery Treatment of Localized Kidney Cancer
Sumanta Kumar Pal, MD, FASCO, joins Rohit Gosain, MD, and Rahul Gosain, MD, to discuss risk stratification and treatment practices for patients with localized kidney cancer following surgery.
Sumanta K. Pal, MD, FASCO, on CONTACT-03 Trial and Investigating Targeted Therapy, Immunotherapy for Patients with RCC
Pal detailed the plan for the CONTACT-03 study and what the research team hopes to see with the data.
Sumanta K. Pal, MD, FASCO, on Moving Forward with Cabozantinib as Treatment for Patients with RCC
Pal discussed the emergence of cabozantinib as a treatment option for patients with renal cell carcinoma and touched on future research around the drug.
Sumanta K. Pal, MD, FASCO, on Tolerability of Lenvatinib and Everolimus to Treat Patients With RCC
Pal detailed the phase 2 trial of lenvatinib at 2 starting doses plus everolimus to treat patients with renal cell carcinoma.
Sumanta K. Pal, MD, FASCO, on Cabozantinib Efficacy in SWOG 1500 for Papillary RCC
Pal discussed findings from the SWOG 1500 trial investigating sunitinib versus either cabozantinib, crizotinib, or savolitinib to treat patients with metastatic papillary RCC.
ctDNA Reveals Genomic Differences of mRCC During First-, Second-Line Therapy
This video examines a new study that looked at genomic alterations in the circulating tumor DNA of patients with metastatic RCC during first- and second-line therapies.
Hitting Prostate Cancer Where It Hurts: Maximizing Control of Osseous Metastases
Enhanced control of osseous metastases with both systemic life-extending therapies and bone-support medications has meaningful clinical impact for prostate cancer patients.
Metastatic Adrenocortical Carcinoma With a Prolonged Response to Mitotane
Adrenocortical carcinoma is a rare disease, with an annual incidence rate ranging from 0.5 to 2.0 cases per million individuals.